Post-earnings recap
Reported
Wed, Mar 7, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Axsome Therapeutics did not report revenue figures, but the stock rose by 4.67% following the earnings report. Investors may be reacting positively to the company's ongoing focus on its clinical programs, despite the lack of detailed financial guidance. The increase in stock price suggests some level of optimism among investors about the company's future prospects.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.31 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management maintained a neutral tone during the call, emphasizing ongoing clinical development efforts. No specific guidance was provided for future performance.
Management did not provide specific revenue guidance for the upcoming period.
The company continues to focus on advancing its clinical programs.